Compare BlackRock TCP Capital Corp (TCPC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

TCPC trades at $3.98 with no recent price movement. The stock shows a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, the company reported negative revenue and net income for 2025, with declining trends projected into 2026. Recent positive developments include Q2 2026 earnings beats and a $523 million portfolio sale that reduced leverage. Analyst sentiment is mixed with 30.77% buy ratings but 69.23% hold recommendations.

TCPC presents a complex investment case with attractive valuation metrics including P/B of 0.62 suggesting potential undervaluation, but significant fundamental challenges with negative revenue and profitability trends. The strategic portfolio sale and ongoing business review offer potential catalysts, though investors face risks from the class action lawsuit and persistent negative cash flow. The dividend yield remains a positive factor for income-focused investors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.